Insight

Ilias Houda: Our EORTC survey on resectability of stage III NSCLC

Ilias Houda/LinkedIn

Dec 26, 2024, 15:22

Ilias Houda: Our EORTC survey on resectability of stage III NSCLC

Ilias Houda, PhD Candidate in Thoracic Oncology at Amsterdam UMC, shared a post on LinkedIn about a recent paper by him and colleagues published in Lung Cancer:

“An international and multidisciplinary EORTC survey on resectability of stage III non-small cell lung cancer”

Authors: Ilias Houdaa, Idris Bahcea, Chris Dickhoff, Benjamin Besse, Lizza Hendriks et al.

“Excited to share the publication of our international and multidisciplinary EORTC survey on resectability of stage III NSCLC!

Our survey aimed to identify areas of controversy and informed, together with the review and clinical cases, the development of a consensual definition of resectable stage III NSCLC, standardizing patient inclusion criteria in future clinical trials.

558 responses were collected from thoracic surgeons, radiation oncologists, medical oncologists, and pulmonologists.

Highlights:

There is no agreement on the resectability of smaller tumors with multi-station N2, or larger tumors with single-station N2.
There is also no agreement on the resectability of invasive T4-tumors with maximum single-station N2.
Smaller tumors with maximum single-station N2 and larger tumors with maximum N1 are considered resectable.
Tumors with bulky N2, invasive N2, or N3 and T4-tumors with multi-station N2 are considered unresectable.

I would like to extend my gratitude to all coauthors, cancer societies that helped distributing the survey, and EORTC Lung Cancer Group which is leading this important Delphi consensus initiative.

Looking forward to the upcoming 3 publications of the review, clinical cases and consensual definition!

Note: figure reflects the survey results and not the consensual definition.”